Literature DB >> 24989890

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Annett Kunze1, Jörg Huwyler1, Gian Camenisch1, Birk Poller2.   

Abstract

Organic anion-transporting polypeptides (OATP) 1B1 and OATP1B3 are drug transporters mediating the active hepatic uptake of their substrates. Because they exhibit overlapping substrate specificities, the contribution of each isoform to the net hepatic uptake needs to be considered when predicting drug-drug interactions. The relative contribution of OATP1B1- and OATP1B3-mediated uptake of statins into hepatocytes was estimated based on either relative transporter protein expression data or relative activity data. Therefore, kinetics of eight statins and OATP1B1- and OATP1B3-specific reference substrates was determined in OATP1B1- and OATP1B3-expressing human embryonic kidney 293 cells and in human cryopreserved hepatocytes. Absolute OATP1B1 and OATP1B3 protein abundance was determined by liquid chromatography-tandem mass spectrometry in all expression systems. Transporter activity data generated in recombinant cell lines were extrapolated to hepatocyte values using relative transporter expression factors (REF) or relative activity factors (RAF). Our results showed a pronounced OATP1B1 and comparatively low OATP1B3 protein expression in the investigated hepatocyte lot. Based on REF scaling, we demonstrated that the active hepatic uptake clearances of reference substrates, atorvastatin, pravastatin, rosuvastatin, and simvastatin were well predicted within twofold error, demonstrating that OATP1B1 and OATP1B3 were major contributors. For other statins, the net hepatic uptake clearance was underpredicted, suggesting the involvement of other hepatic uptake transporters. Summarized, we showed that REF- and RAF-based predictions were highly similar, indicating a direct transporter expression-activity relationship. Moreover, we demonstrated that the REF-scaling method provided a powerful tool to quantitatively assess the transporter-specific contributions to the net uptake clearance of statins in hepatocytes.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989890     DOI: 10.1124/dmd.114.058412

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

2.  Estimating In Vivo Fractional Contribution of OATP1B1 to Human Hepatic Active Uptake by Mechanistically Modeling Pharmacogenetic Data.

Authors:  Rui Li
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

3.  Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.

Authors:  Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Sreedevi Boggarapu; Gangadhar Sunkara
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

Review 4.  Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.

Authors:  Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Sreedevi Boggarapu; Gangadhar Sunkara
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

5.  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Authors:  Xiaoyan Chu; Grace Hoyee Chan; Robert Houle; Meihong Lin; Jocelyn Yabut; Christine Fandozzi
Journal:  AAPS J       Date:  2022-03-21       Impact factor: 4.009

6.  Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin.

Authors:  Valentina M Fokina; Svetlana Patrikeeva; Xiao-Ming Wang; Saki Noguchi; Masatoshi Tomi; Jörg König; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  J Pharm Sci       Date:  2021-09-28       Impact factor: 3.534

Review 7.  Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.

Authors:  Carl Petersson; Xin Zhou; Joerg Berghausen; David Cebrian; Michael Davies; Kevin DeMent; Peter Eddershaw; Arian Emami Riedmaier; Alix F Leblanc; Nenad Manveski; Punit Marathe; Panteleimon D Mavroudis; Robin McDougall; Neil Parrott; Andreas Reichel; Charles Rotter; David Tess; Laurie P Volak; Guangqing Xiao; Zheng Yang; James Baker
Journal:  AAPS J       Date:  2022-07-19       Impact factor: 3.603

8.  Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist).

Authors:  Philip Sandoval; Bei-Ching Chuang; John K Fallon; Philip C Smith; Swapan K Chowdhury; Robert J Griffin; Cindy Q Xia; Shinji Iwasaki; Paresh P Chothe
Journal:  AAPS J       Date:  2022-09-19       Impact factor: 3.603

9.  Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors.

Authors:  A Emami Riedmaier; O Burk; B A C van Eijck; E Schaeffeler; K Klein; S Fehr; S Biskup; S Müller; S Winter; U M Zanger; M Schwab; A T Nies
Journal:  Pharmacogenomics J       Date:  2015-08-04       Impact factor: 3.550

10.  In Vivo-to-In Vitro Extrapolation of Transporter-Mediated Renal Clearance: Relative Expression Factor Versus Relative Activity Factor Approach.

Authors:  Aditya R Kumar; Bhagwat Prasad; Deepak Kumar Bhatt; Sumathy Mathialagan; Manthena V S Varma; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-04-06       Impact factor: 3.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.